BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...Wingless-type MMTV integration site family member BioCentury Staff Viaskin Peanut (DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...billion in market cap Monday after reporting data from its Phase II study of KarXT xanomeline/trospium chloride...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...xanomeline, which is an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride...
...CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 Paul Bonanos, Associate Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...
BioCentury | Jun 28, 2019
Financial News

June 28 Financial Quick Takes: Karuna rises after IPO; plus Chi-Med, BeiGene and more

...Data are due this year from a Phase II trial of Karuna's lead candidate KarXT xanomeline/trospium chloride...
BioCentury | May 31, 2019
Financial News

New IPO filings include Adaptive, Morphic

...By late 2019, Karuna expects data from a Phase II trial of lead program KarXT xanomeline/trospium chloride...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...to date. By late 2019, Karuna expects data from a Phase II trial of KarXT xanomeline/trospium chloride...
...receptors M1 and M4 that has shown efficacy in CNS disorders, by combining it with trospium chloride...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

...Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including...
...of CHRM1 and CHRM4 that has shown efficacy in CNS disorders, by combining it with trospium chloride...
...CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 Paul Bonanos, Assistant Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...
BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

...and Karuna Chairman Steven Paul, as well as undisclosed other backers. Karuna believes its KarXT xanomeline/trospium chloride...
...xanomeline, which is an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride...
...company would consider licensing other assets opportunistically. Paul Bonanos, Assistant Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...
BioCentury | Aug 3, 2018
Financial News

Karuna raises $42M series A

...Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT xanomeline/trospium chloride...
...candidate combines xanomeline, an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and CHRM4, with trospium chloride...
...Lilly and Co. (NYSE:LLY). Karuna Pharmaceuticals Inc., Boston, Mass. Sandi Wong KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Eli...
BioCentury | Aug 2, 2018
Financial News

Karuna raises $42M series A

...Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT xanomeline/trospium chloride...
...candidate combines xanomeline, an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and CHRM4, with trospium chloride...
...license to xanomeline from Eli Lilly and Co. (NYSE:LLY). Sandi Wong KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...
Items per page:
1 - 10 of 103